Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Srivichaivejvivat Public Company Limited (VIH.BK)
Krathum Baen, TH
Srivichaivejvivat Public Company Limited, along with its subsidiaries, manages a network of hospitals throughout Thailand. The company provides a wide range of medical treatments addressing diverse health needs, including specialized centers for orthopedics, general surgery, urology, and comprehensive brain care. Its services also extend to cardiovascular medicine, nephrology, endocrinology, dermatology, and neurology, alongside general medical clinics, dental services, physical rehabilitation, and plastic surgery. Beyond its core healthcare provision, the company also operates a vocational training institution. Established in 1987, the firm's base of operations is in Krathum Baen, Thailand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.65% | -5.75% | -6.29% | -8.38% | +5.13% | -3.53% | +7.89% | +0.00% | -6.82% | +4.46% | +187.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+9.0% Q1'26: +5.4% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+35.9% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+8.5% Q1'26: +17.0% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+16.4% ★ Q1'26: +17.0% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+15.7% ★ Q1'26: +15.7% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+2.6% Q1'26: +1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×0.10× ★ Q1'26: 0.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
2.81B
est: 2.97B (-5.3%)
|
3.06B
est: 2.97B (+3.1%)
|
2.97B
2.97B – 2.97B
+0.0% YoY
|
3.17B
3.17B – 3.17B
+6.7% YoY
|
3.44B
3.44B – 3.44B
+8.4% YoY
|
| EBITDA |
578.77M
est: 766.30M (-24.5%)
|
688.54M
est: 766.30M (-10.1%)
|
766.30M
766.30M – 766.30M
+0.0% YoY
|
817.67M
817.67M – 817.67M
+6.7% YoY
|
886.58M
886.58M – 886.58M
+8.4% YoY
|
| EBIT |
399.68M
est: 606.63M (-34.1%)
|
502.05M
est: 606.63M (-17.2%)
|
606.63M
606.63M – 606.63M
+0.0% YoY
|
647.29M
647.29M – 647.29M
+6.7% YoY
|
701.84M
701.84M – 701.84M
+8.4% YoY
|
| Net Income |
314.38M
est: 340.76M (-7.7%)
|
436.19M
est: 340.76M (+28.0%)
|
340.76M
340.76M – 340.76M
+0.0% YoY
|
389.44M
389.44M – 389.44M
+14.3% YoY
|
359.02M
359.02M – 359.02M
-7.8% YoY
|
| SGA |
340.96M
est: 330.42M (+3.2%)
|
324.49M
est: 330.42M (-1.8%)
|
330.42M
330.42M – 330.42M
+0.0% YoY
|
352.57M
352.57M – 352.57M
+6.7% YoY
|
382.29M
382.29M – 382.29M
+8.4% YoY
|
| EPS |
0.53
est: 0.56 (-5.4%)
|
0.72
est: 0.56 (+28.6%)
|
0.56
0.56 – 0.56
+0.0% YoY
|
0.64
0.64 – 0.64
+14.3% YoY
|
0.59
0.59 – 0.59
-7.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 39.5K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 28.7K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Associate Vichai Vanadurongwan FIMS | Executive Chairman of the Board of Directors | 434.0K | — |
| Assist. Saisunee Vanadurongwan | Vice Chairman & Chief Executive Officer | 355.0K | — |
| Vilawan Vanadurongvan | Executive Director | 250.0K | female |
| Mongkon Wanitphakdeedecha | Deputy Chief Executive Officer & Executive Director | 230.0K | male |
| Prut Rojmahamongkol | Deputy Chief Executive Officer & Executive Director | 230.0K | male |
| Pongsak Vathana | Deputy Chief Executive Officer & Advisory of Board of Director | 30.0K | male |
| Rachada Fongtanakit | Company Secretary | — | — |
| Sakda Tangchitwatanakorn | Chief Financial Officer | — | male |
| Chinapat Upaijit | Internal Audit Manager | — | male |
| Chalanthorn Trakulweerasak | Company Secretary | — | female |
| Korn Talthip | Deputy Chief Executive Officer | — | male |
| Nichapa Roenthongdee | Finance Accounting Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIH.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
